China’s Hefei has bought the rights to market the oral insulin capsules developed by Israel’s Oramed on completion of Phase III trials. In a deal worth over $50 million, Hefei gets exclusive rights to market the diabetes treatment in China, Hong Kong and Macau.
http://www.reuters.com/article/oramed-china-idUSL8N13O0AO20151130#yPie1PeLX28uusFZ.97